Brainsway gets FDA approval to begin bipolar disorder trial
Brainsway has received investigational device exemption approval from the US Food and Drug Administration (FDA) to initiate a multicentre clinical trial to investigate the efficacy of its deep transcranial magnetic stimulation device as a treatment for bipolar disorder.
Brainsway has received investigational device exemption approval from the US Food and Drug Administration (FDA) to initiate a multicentre clinical trial to investigate the efficacy of its deep transcranial magnetic stimulation device as a treatment for bipolar disorder.
The device enables non-invasive depolarisation or hyperpolarisation of brain neurons.
Medical Device Network Excellence Awards - Nominations Closed
Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact
Excellence in Action Awarded for Innovation in Remote Hearing Diagnostics, hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.
